Shanghai Ruijing Biotechnology
Focuses on the molecular diagnosis of thyroid tumors
About Shanghai Ruijing Biotechnology
Shanghai Ruijing Biotechnology Co., Ltd. (Rigen Bio), established in August 2017, is a high-tech enterprise focused on providing molecular diagnostic solutions for precision medicine, with a particular specialization in thyroid cancer. The company was founded by Mr. Hong Gendong, who serves as the legal representative and brings over two decades of experience in commercializing clinical products and team management, including a successful career at Boehringer Ingelheim. His commercial expertise is complemented by a strong R&D team led by CSO Dr. Yang Feng, a Peking University molecular medicine Ph.D., and CTO Dr. Shi Han, a Tsinghua University graduate with a Ph.D. from Northwestern University.
The company operates in the rapidly growing field of in-vitro diagnostics (IVD), specifically targeting the significant clinical need for better diagnosis and management of thyroid nodules and cancer. Its business model integrates the entire process from research and development to manufacturing, sales, and service. Rigen Bio generates revenue by selling its diagnostic products and providing testing services to healthcare institutions. Its client base primarily consists of large, top-tier (Class A Grade 3) general and specialized cancer hospitals across more than fifteen provinces in China.
Rigen Bio has developed a comprehensive product portfolio that covers the entire clinical pathway for thyroid cancer, from initial diagnosis to post-operative monitoring. A cornerstone achievement is the 2023 NMPA approval of its “Human BRAF/TERT/CCDC6-RET Gene Mutation Detection Kit (Fluorescence PCR method),” the first-of-its-kind product approved in China for pre-operatively assessing indeterminate thyroid nodules. The company's offerings also include a specially designed disposable thyroid biopsy needle, various multi-gene qPCR and Next-Generation Sequencing (NGS) testing kits, and the Thyroscan® classifier, which uses machine learning to assess nodule malignancy. These products provide an integrated solution for physicians, aiding in the accurate classification of thyroid nodules, which helps to avoid unnecessary surgeries and reduces the burden on healthcare resources.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Minhang District, China
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 25.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Precision Medicine, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Nov 2025 | $14M | $55M | Efung Capital | ↗ |
| EARLY VC✓Equity / VC | Nov 2023 | $2.8M | $69M | Boyuan Capital · Jinsheng Investment | ↗ |
Growth signals
Latest recorded traffic for Shanghai Ruijing Biotechnology is 410 monthly website visits, up 127.8% over the last three months. Shanghai Ruijing Biotechnology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
- GIGuotai Junan Innovation Investment
- JIJinsheng Investment
Boyuan Capital- ECEfung Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shanghai Ruijing Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shanghai Ruijing Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







